ITGAM and neoplasm: Anti-PK2 antibody treatment also reduced the number of circulating and tumor-infiltrating CD11b+Gr1+ myeloid cells, including bone marrow-derived macrophages, which have been shown to mediate refractoriness to anti-VEGF therapies in several mouse xenograft tumor models [8], [37].